Osteosarcoma (Oncology) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteosarcoma – Drugs In Development, 2021, provides an overview of the Osteosarcoma (Oncology) pipeline landscape.

Osteosarcoma is the most common cancer of the bone that destroys tissue and weakens the bone. It is developed from immature bone cells that normally form new bone tissue. Symptoms include pain, bone fractures, swelling, redness and limitation of motion of joints. Risk factors include age, gender, family history and Li-Fraumeni syndrome. Treatment includes chemotherapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteosarcoma – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Osteosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 37, 24, 1, 37 and 7 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 7 and 3 molecules, respectively.

Osteosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Osteosarcoma (Oncology).

– The pipeline guide reviews pipeline therapeutics for Osteosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Osteosarcoma (Oncology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Osteosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Osteosarcoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Osteosarcoma (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Osteosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Aadi Bioscience Inc

Actuate Therapeutics Inc

ADCendo ApS

Advanced BioDesign

Advaxis Inc

Advenchen Laboratories LLC

Allarity Therapeutics A/S

AntiCancer Inc

APEIRON Biologics AG

API Co Ltd

Arrowhead Pharmaceuticals Inc

Astex Therapeutics Ltd

AstraZeneca Plc

Atlanthera

Aurora BioPharma Inc

Autolus Therapeutics Plc

Bayer AG

Table of Contents

Table of Contents

Introduction

Osteosarcoma - Overview

Osteosarcoma - Therapeutics Development

Osteosarcoma - Therapeutics Assessment

Osteosarcoma - Companies Involved in Therapeutics Development

Osteosarcoma - Drug Profiles

Osteosarcoma - Dormant Projects

Osteosarcoma - Discontinued Products

Osteosarcoma - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Osteosarcoma, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Osteosarcoma – Pipeline by Aadi Bioscience Inc, 2021

Osteosarcoma – Pipeline by Actuate Therapeutics Inc, 2021

Osteosarcoma – Pipeline by ADCendo ApS, 2021

Osteosarcoma – Pipeline by Advanced BioDesign, 2021

Osteosarcoma – Pipeline by Advaxis Inc, 2021

Osteosarcoma – Pipeline by Advenchen Laboratories LLC, 2021

Osteosarcoma – Pipeline by Allarity Therapeutics A/S, 2021

Osteosarcoma – Pipeline by AntiCancer Inc, 2021

Osteosarcoma – Pipeline by APEIRON Biologics AG, 2021

Osteosarcoma – Pipeline by API Co Ltd, 2021

Osteosarcoma – Pipeline by Arrowhead Pharmaceuticals Inc, 2021

Osteosarcoma – Pipeline by Astex Therapeutics Ltd, 2021

Osteosarcoma – Pipeline by AstraZeneca Plc, 2021

Osteosarcoma – Pipeline by Atlanthera, 2021

Osteosarcoma – Pipeline by Aurora BioPharma Inc, 2021

Osteosarcoma – Pipeline by Autolus Therapeutics Plc, 2021

Osteosarcoma – Pipeline by Bayer AG, 2021

Osteosarcoma – Pipeline by Bicycle Therapeutics Plc, 2021

Osteosarcoma – Pipeline by BioAtla Inc, 2021

Osteosarcoma – Pipeline by BioEclipse Therapeutics Inc, 2021

Osteosarcoma – Pipeline by BioMarck Pharmaceuticals Ltd, 2021

Osteosarcoma – Pipeline by Epeius Biotechnologies Corp, 2021

Osteosarcoma – Pipeline by Exelixis Inc, 2021

Osteosarcoma – Pipeline by GlaxoSmithKline Plc, 2021

Osteosarcoma – Pipeline by GlycoMimetics Inc, 2021

Osteosarcoma – Pipeline by Hebei Senlang Biotechnology Co Ltd, 2021

Osteosarcoma – Pipeline by HengRui YuanZheng Bio-Technology Co Ltd, 2021

Osteosarcoma – Pipeline by Hillstream BioPharma Inc, 2021

Osteosarcoma – Pipeline by Idera Pharmaceuticals Inc, 2021

Osteosarcoma – Pipeline by ImmunityBio Inc, 2021

Osteosarcoma – Pipeline by Incuron LLC, 2021

Osteosarcoma – Pipeline by Innova Therapeutics Inc, 2021

Osteosarcoma – Pipeline by Intezyne Inc, 2021

Osteosarcoma – Pipeline by Iovance Biotherapeutics Inc, 2021

Osteosarcoma – Pipeline by Ipsen SA, 2021

Osteosarcoma – Pipeline by Isofol Medical AB, 2021

Osteosarcoma – Pipeline by Iterion Therapeutics Inc, 2021

Osteosarcoma – Pipeline by ITM Isotopen Technologien Munchen AG, 2021

Osteosarcoma – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021

Osteosarcoma – Pipeline by Joint Biosciences Ltd, 2021

Osteosarcoma – Pipeline by K-Group Beta Inc, 2021

Osteosarcoma – Pipeline by Komipharm International Co Ltd, 2021

Osteosarcoma – Pipeline by Kyowa Kirin Co Ltd, 2021

Osteosarcoma – Pipeline by MacroGenics Inc, 2021

Osteosarcoma – Pipeline by Mana Therapeutics Inc, 2021

Osteosarcoma – Pipeline by Mateon Therapeutics Inc, 2021

Osteosarcoma – Pipeline by MD Biosciences GmbH, 2021

Osteosarcoma – Pipeline by MediaPharma SRL, 2021

Osteosarcoma – Pipeline by Merck & Co Inc, 2021

Osteosarcoma – Pipeline by Merck KGaA, 2021

Osteosarcoma – Pipeline by MetCure Therapeutics LLC, 2021

Osteosarcoma – Pipeline by Moleculin Biotech Inc, 2021

Osteosarcoma – Pipeline by Nanjing Aimeifei Biomedical Technology Co Ltd, 2021

Osteosarcoma – Pipeline by Nektar Therapeutics, 2021

Osteosarcoma – Pipeline by Nkarta Inc, 2021

Osteosarcoma – Pipeline by Novartis AG, 2021

Osteosarcoma – Pipeline by Oncolys BioPharma Inc, 2021

Osteosarcoma – Pipeline by Ono Pharmaceutical Co Ltd, 2021

Osteosarcoma – Pipeline by OS Therapies LLC, 2021

Osteosarcoma – Pipeline by PEEL Therapeutics Inc, 2021

Osteosarcoma – Pipeline by Pfizer Inc, 2021

Osteosarcoma – Pipeline by Pimera Inc, 2021

Osteosarcoma – Pipeline by QSAM Therapeutics Inc, 2021

Osteosarcoma – Pipeline by Reven Pharmaceuticals Inc, 2021

Osteosarcoma – Pipeline by Scancell Holdings Plc, 2021

Osteosarcoma – Pipeline by Secura Bio Inc, 2021

Osteosarcoma – Pipeline by Shionogi & Co Ltd, 2021

Osteosarcoma – Pipeline by Singh Biotechnology LLC, 2021

Osteosarcoma – Pipeline by Sorrento Therapeutics Inc, 2021

Osteosarcoma – Pipeline by Taiho Pharmaceutical Co Ltd, 2021

Osteosarcoma – Pipeline by Taithera Inc, 2021

Osteosarcoma – Pipeline by Transtarget Inc, 2021

Osteosarcoma – Pipeline by Umoja BioPharma Inc, 2021

Osteosarcoma – Pipeline by United Therapeutics Corp, 2021

Osteosarcoma – Pipeline by Vaccinex Inc, 2021

Osteosarcoma – Pipeline by Veana Therapeutics LLC, 2021

Osteosarcoma – Pipeline by Y-mAbs Therapeutics Inc, 2021

Osteosarcoma – Pipeline by Zentalis Pharmaceuticals Inc, 2021

Osteosarcoma – Dormant Projects, 2021

Osteosarcoma – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Osteosarcoma, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports